Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients

An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study

“…The tri-monthly transfusion rate in the 3 months prior to initiation was 6% compared with a lower rate of 3% in the first 3 months after initiation. While a causal relationship cannot be established in an observational study, these data are consistent with the literature [ 1 , 18 , 25 ].…”

An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study

“…The tri-monthly transfusion rate in the 3 months prior to initiation was 6% compared with a lower rate of 3% in the first 3 months after initiation. While a causal relationship cannot be established in an observational study, these data are consistent with the literature [ 1 , 18 , 25 ].…”

Prevalence of Nutritional Anaemia in Type 2 Diabetes Mellitus in the Absence of Renal Impairment

“…The focus of this study is on the importance of tailoring treatment guidelines for incorporating hematology assessments by age and glycemic control to optimize diabetes control in adult populations [ 13 ]. Anemia and diabetes mellitus are two terms that have been overused and extensively discussed in medical research.…”

Dose of Erythropoiesis-Stimulating Agents and Adverse Outcomes in CKD: A Metaregression Analysis

“…A recent retrospective cohort study found that, at higher hematocrit levels, an increased risk of death was associated with greater ESA and iron use 66 . Prior systematic reviews on this topic either did not explore the potential effect of ESA dose on mortality or other adverse outcomes 2,6,9–15 or reported that the data were insufficient for this analysis 7 .…”

An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study

“…The tri-monthly transfusion rate in the 3 months prior to initiation was 6% compared with a lower rate of 3% in the first 3 months after initiation. While a causal relationship cannot be established in an observational study, these data are consistent with the literature [ 1 , 18 , 25 ].…”

Prevalence of Nutritional Anaemia in Type 2 Diabetes Mellitus in the Absence of Renal Impairment

“…The focus of this study is on the importance of tailoring treatment guidelines for incorporating hematology assessments by age and glycemic control to optimize diabetes control in adult populations [ 13 ]. Anemia and diabetes mellitus are two terms that have been overused and extensively discussed in medical research.…”

Dose of Erythropoiesis-Stimulating Agents and Adverse Outcomes in CKD: A Metaregression Analysis

“…A recent retrospective cohort study found that, at higher hematocrit levels, an increased risk of death was associated with greater ESA and iron use 66 . Prior systematic reviews on this topic either did not explore the potential effect of ESA dose on mortality or other adverse outcomes 2,6,9–15 or reported that the data were insufficient for this analysis 7 .…”

An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study

“…The tri-monthly transfusion rate in the 3 months prior to initiation was 6% compared with a lower rate of 3% in the first 3 months after initiation. While a causal relationship cannot be established in an observational study, these data are consistent with the literature [ 1 , 18 , 25 ].…”

Prevalence of Nutritional Anaemia in Type 2 Diabetes Mellitus in the Absence of Renal Impairment

“…The focus of this study is on the importance of tailoring treatment guidelines for incorporating hematology assessments by age and glycemic control to optimize diabetes control in adult populations [ 13 ]. Anemia and diabetes mellitus are two terms that have been overused and extensively discussed in medical research.…”

Dose of Erythropoiesis-Stimulating Agents and Adverse Outcomes in CKD: A Metaregression Analysis

“…A recent retrospective cohort study found that, at higher hematocrit levels, an increased risk of death was associated with greater ESA and iron use 66 . Prior systematic reviews on this topic either did not explore the potential effect of ESA dose on mortality or other adverse outcomes 2,6,9–15 or reported that the data were insufficient for this analysis 7 .…”